We are excited to announce that we have begun construction on a new facility in Philadelphia for cGMP manufacture of allogeneic and autologous cell-based therapeutics.  The 45,000-square-foot facility, anticipated to become operational in the second quarter of 2015, will provide increased capacity and capabilities to serve the cell therapy industry for both clinical and commercial products.

Built using advanced modular design —with flexible clean room technology, disposable equipment and microcarrier cell culture systems — the new facility will be located in the Philadelphia Navy Yard near WuXi AppTec’s existing center for biopharmaceutical services.  The new facility will build on our current 16,000-square-foot space for cGMP cell therapy manufacturing and complement our existing facility and capabilities in Philadelphia, which include analytical chemistry, cell banking, cell characterization, molecular biology, and lot release testing.

We are committed to helping our customers and collaborators bring these important therapies to market faster by providing comprehensive single-source services to meet the broad range of cell therapy development and manufacturing needs.

 

Related links:

WuXi’s GMP Manufacturing of Cellular Therapeutics Service

1 COMMENT